



LUNG-MAP

A lung cancer precision medicine trial

VOLUME 29 | FALL 2025

NEWSLETTER

WWW.LUNG-MAP.ORG

Leading with the Leaders

No, your Lung-MAP Newsletter is *not* backwards — with this issue, we've put our enrollment leaders on the first page instead of the last. They help make Lung-MAP work, and the study team is grateful!


AS OF DECEMBER 1, 2025, LUNGMAP HAS LOGGED:

3,833 screening registrations **2,039** sub-study assignments **556** sub-study registrations

LUNGMAP ENROLLMENT LEADERS: DECEMBER 2024 – NOVEMBER 2025

SITES

Palo Alto Medical Foundation-Sunnyvale (CA)	16
University of New Mexico Cancer Center (NM)	16
Edwards Comprehensive Cancer Center (WV)	15
Sutter Pacific Medical Foundation (CA)	11
Palo Alto Medical Foundation – Santa Cruz (CA)	10
Dartmouth Hitchcock Med Cntr/Dartmouth CC (NH)	8
Mercy Hospital South (MO)	8
UPMC Hillman Cancer Center – Monroeville (PA)	7
Palo Alto Medical Foundation Health Care (CA)	6
Ridley-Tree Cancer Center (CA)	6
Saint Mary's Medical Center (WV)	6
University of Rochester (NY)	6



INVESTIGATORS

Moises Harari-Turquie	University of New Mexico Cancer Center (NM)	12
Toni Pacioles	Edwards Comprehensive Cancer Center (WV)	10
Kim-Son Nguyen	Palo Alto Medical Foundation – Sunnyvale (CA)	9
Zeyad Kanaan	Sutter Pacific Medical Foundation (CA)	8
Glenn Wong	Palo Alto Medical Foundation – Santa Cruz (CA)	7
Ivy Riano Monsalve	Dartmouth Hitchcock Med Cntr/Dartmouth CC (NH)	6
Tianhong Li	Mather VA Med Center (CA) and UC Davis CCC (CA)	6
Chao Huang	U Kansas Hospital-Westwood Cancer Center (KS)	5
Muhammad Omer Jamil	Edwards Comprehensive Cancer Center (WV)	5
Huy Nguyen	Palo Alto Med Foundation – Sunnyvale (CA) and Fremont – Rideout CC (CA)	5
Brittany Rogers	Malcom Randall VA Medical Center (FL)	5

REGISTERING ASSOCIATES

Casey Holden	Sutter Pacific Medical Foundation (CA)	11
Kimberly Lynn Flores	University of New Mexico Cancer Center (NM)	9
Selina Perez	Palo Alto Medical Foundation-Santa Cruz (CA)	9
Nerissa Charland	Dartmouth Hitchcock Med Cntr/Dartmouth CC (NH) and Dartmouth CC – North (NH)	8
Keshia Noelle Bowen	Edwards Comprehensive Cancer Center (WV)	7
Christos Derizotis	University of New Mexico Cancer Center (NM)	7
Michele E. Kildare	Palo Alto Medical Foundation – Sunnyvale (CA) and Palo Alto Medical Foundation – Santa Cruz (CA)	7
Priscilla Ellen Hall	University of Rochester (NY)	6
Linda Mireles	Palo Alto Medical Foundation – Sunnyvale (CA)	6
Beverly Ann Smith	Saint Mary's Medical Center (WV)	6
Danielle Werle	Mercy Hospital South (MO)	6

LEARN MORE AT WWW.LUNG-MAP.ORG



LUNGMAP ENROLLMENT LEADERS *CONTINUED*

SITES ENROLLING THEIR FIRST PATIENT TO LUNGMAP *(SINCE SEPTEMBER 12TH)*

Congratulations to the following sites, which have recently had their first LUNGMAP enrollment. Welcome!

- Advocate Christ Medical Center (IL)
- Advocate Lutheran General Hospital (IL)
- Advocate Outpatient Center – Aurora (IL)
- Emory University Hospital Midtown (GA)
- Fred Hutch Ca Ctr at Northwest Hospital (WA)
- Gulf Health Hospitals/Infirmary Cancer Care – Malbis (AL)
- Kaiser Permanente – San Diego Zion (CA)
- Ohio St Univ Comprehensive Cancer Center (OH)
- Vince Lombardi Cancer Clinic – Two Rivers (WI)

TOP-ACCRUING SITE(S) TO EACH SUB-STUDY

S1800E

- Washington University School of Medicine (MO)

S1900G

- Northwestern University (IL)
- ProMedica Flower Hospital (OH)

S1900J

- Queen's Medical Center (HI)
- Rocky Mountain Regional VA Medical Center (CO)
- Sechler Family Cancer Center (PA)

S1900K

- Memorial Sloan Kettering Cancer Center (NY)

S1900G Revision: Screening Options Expanded

With a September protocol revision, [S1900G](#)'s screening options have expanded to include all genomic testing platforms outlined in LUNGMAP revision #9 (Lung-MAP 3.0).


The S1900G September revision (PVD 07/10/25) also eases one eligibility criterion: whether a patient has uncontrolled hypertension is now determined by the treating physician (previously,

this was defined in the protocol).

Remember that for S1900G eligibility, MET amplification must be documented with tissue or blood obtained *after* disease progression on osimertinib.

Do you have patients now being treated with osimertinib who can be tested for S1900G eligibility at progression?


Resistance mechanisms to first-line osimertinib



S1800E Non-Match News

Revision #1: The first revision to the [S1800E](#) protocol (PVD 10/02/25) has been posted. The sub-study now allows for archival tissue submission, and the eligibility criteria have been updated to clarify what types of prior targeted therapy are allowed and to make more patients who have been treated for autoimmune disease eligible to enroll.

Just the FAQs: A Frequently Asked Questions (FAQs) document for this non-match sub-study has just been posted to [the Lung-MAP Training page \(login-free\)](#) and [the S1800E page on CTSU.org](#).




S1900J UPDATE: Easier Screening, Broader Eligibility

A recent revision to [S1900J](#) (PVD 06/25/25) opens new genomic screening options for assigning patients to the sub-study. While screening for S1900J was previously limited to Foundation Medicine testing, results from the full range of Lung-MAP 3.0-accepted next-generation sequencing testing platforms can now be used.

The sub-study's eligibility criteria have also been revised and now allow *KRAS*-activating mutations (other than *KRAS* G12C).

S1900J enrolls patients with MET-amplified NSCLC to treatment with amivantamab hyaluronidase administered subcutaneously. Is it open at your site?



In the Wings: S1900N

Lung-MAP's next sub-study, S1900N, is approaching activation, expected to open in the first quarter of 2026.

It will enroll patients with advanced NSCLC with almost any *actionable* genomic alteration – that is, an alteration for which a targeted therapy is available.

More than one-third of NSCLC cases fall into this group, but virtually all eventually develop resistance to targeted therapy.

These patients may be eligible for S1900N. It's a randomized three-arm Phase II that will test two agents alone or in combination in patients previously treated with a targeted therapy plus platinum-based chemo.

Stay tuned for details!

Her wealth of experience is just part of what has made her so effective as a patient advocate for Lung-MAP.

Judy Johnson, Patient Advocate Extraordinaire

Patient advocates and advocacy organizations have been integral partners in the Lung-MAP endeavor from Day 1. For most of the last decade, the primary advocate representing patients when Lung-MAP protocols are being crafted has been Judy Johnson, MBA.

As lung cancer advocate for SWOG Cancer Research Network since early 2016, she has also served as Lung-MAP's patient advocate. But SWOG advocates are limited to two five-year terms, and Judy will be stepping down from the role when her 10 years are up in February.

During her tenure, she's championed the patient perspective in the development of some 15 Lung-MAP sub-studies, plus overhauls of the LUNGMAP (and before it the S1400) screening protocol.

Herself a survivor of breast cancer, Judy also served as a caregiver for her father after he was diagnosed with Stage IV non-small cell lung cancer. Among her

several careers, she has spent time in the clinic as a research study coordinator, managing lung cancer trials for an NCI-designated comprehensive cancer center. She has sat on a university's institutional review board as well and has been a member of several NCI steering committees.

Her wealth of experience is just part of what has made her so effective as a patient advocate for Lung-MAP. All of us involved in the trial – along with the patients enrolled to our sub-studies – owe her a huge debt of gratitude.

The search for SWOG's new lung cancer and Lung-MAP advocate is underway. Applicants should be aware – Judy will be a tough act to follow.



Judy Johnson, MBA

Since 2016, in addition to contributing to all Lung-MAP studies, Judy Johnson, MBA, has also served as patient advocate for the other trials developed by SWOG's lung committee, which over the last decade has been among the group's most productive research committees.

CONTACT US

Request Review of New NGS Test LungmapNGS@swog.org
General Medical Questions LUNGMAP@swog.org
Protocol & Regulatory Questions jbeeler@swog.org
Eligibility & Data Submission Questions LUNGMAPQuestion@crab.org
Central Monitoring Questions centralmonitorquestion@crab.org
Quality Assurance Auditing Questions qamail@swog.org

Funding Questions funding@swog.org
S1800E Study Chairs S1800EMedicalQuery@swog.org
S1900G Study Chairs S1900GMedicalQuery@swog.org
S1900J Study Chairs S1900JMedicalQuery@swog.org
S1900K Study Chairs S1900KMedicalQuery@swog.org